Adoptive Cellular Therapy: A Therapeutic Reality?

References

• Higano, CS., Brixey, M., Bryant, E.M., et al. (1990) "Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplan-tation. A case report of a probable graft-versus-leukemia effect", Transplantation 50(1), 175–177.
   PubMed Web of Science ®Google Scholar
• Collins, Jr., R.H., Rogers, Z.R., Bennett, M., Kumar, V, Nikein, A. and Fay, J.W. (1992) "Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect fol-lowing abrupt discontinuation of immunosuppression", Bone marrow Transplant. 10(4), 391–395.
   PubMed Web of Science ®Google Scholar
• Garban, F., Attal, M., Rossi, J.F., Payen, C., Fegueux, N. and Sotto, J.J. (2001) "Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation", Leukemia 15(4), 642–646.
   PubMed Web of Science ®Google Scholar
• Odom, L.F., August, C.S., Githens, J.H., et al. (1978) "Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?", Lancet 2(8089), 537–540.
   PubMed Web of Science ®Google Scholar
• Sullivan, KM., Weiden,Storb, R., et al. (1989) "Influenceof acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia", Blood 73(6), 1720–1728.
   PubMed Web of Science ®Google Scholar
• Gale, R.P., Horowitz, UM., Ash, R.C., et al. (1994) "Identical-twin bone marrow transplants for leukemia", Ann. Intern. Med. 120(8), 646–652.
   PubMed Web of Science ®Google Scholar
• Kolb, H.J., Schattenberg, A., Goldman, J.M., et al. (1995) "Graft-versus-leukemia effect of donor lymphocyte transfu-sions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leuke-mia", Blood 86(5), 2041–2050.
   PubMed Web of Science ®Google Scholar
• Collins, Jr, R.H., Shpilberg, O., Drobyski, W.R., et al. (1997) "Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation", J. Clin. Oncol. 15(2), 433–444.
   PubMed Web of Science ®Google Scholar
• Khouri, IF., Lee, MS., Romaguera, J., Mirza, N., et al. (1999) "Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy", Ann. Oncol. 10(11), 1293–1299.
   PubMed Web of Science ®Google Scholar
• Devine, S.M., Hoffman, R., Verma, A., et al. (2002) "Allogeneic blood cell transplantation following reduced-intensity con-ditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia", Blood 99(6), 2255–2258.
   PubMed Web of Science ®Google Scholar
• van Besien, K.W., de Lima, M., Giralt, S.A., et al. (1997) "Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect", Bone Marrow Transplant. 19(10), 977–982.
   PubMed Web of Science ®Google Scholar
• Collins, Jr, R.H., Goldstein, S., Giralt, S., et al. (2000) "Donor leukocyte infusions in acute lymphocytic leukemia", Bone Marrow Transplant. 26(5), 511–516.
   PubMed Web of Science ®Google Scholar
• Childs, R., Chernoff, A., Contentin, N., et al. (2000) "Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation", N. Engl. J. Med. 343(11), 750–758.
   PubMed Web of Science ®Google Scholar
• Fontaine, P., Roy-Proulx, G., Knafo, L., Baron, C., Roy, D.C. and Perreault, C. (2001) "Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease", Nat. Med. 7(7), 789–794.
   PubMed Web of Science ®Google Scholar
• Pion, S., Fontaine, P., Baron, C., Gyger, M. and Perreault, C. (1995) "Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy", J. Clin. Investig. 95(4), 1561–1568.
   PubMed Web of Science ®Google Scholar
• Sullivan, K.M., Storb, R., Buckner, C.D., et al. (1989) "Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms", N. Engl. J. Med. 320(13), 828–834.
   PubMed Web of Science ®Google Scholar
• Johnson, B.D. and Truitt, R.L. (1995) "Delayed infusion of immunocompetent donor cells after bone marrow transplan-tation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease", Blood 85(11), 3302–3312.
   PubMed Web of Science ®Google Scholar
• Kernan, N.A., Collins, N.H., Juliano, L., Cartagena, T., Dupont, B. and O'Reilly, R.J. (1986) "Clonable T lympho-cytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host-disease", Blood 68(3), 770–773.
   PubMed Web of Science ®Google Scholar
• Mackinnon, S., Papadopoulos, E.B., Carabasi, M.H., et al. (1995) "Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host-disease", Blood 86(4), 1261–1268.
   PubMed Web of Science ®Google Scholar
• Papadopoulos, E.B., Ladanyi, M., Emanuel, D., et al. (1994) "Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation", N. Engl. J. Med. 330(17), 1185–1191.
   PubMed Web of Science ®Google Scholar
• Jiang, Y.Z., Kanfer, E.J., Macdonald, D., Cullis, JO., Goldman, J.M. and Barrett, A.J. (1991) "Graft-versus-leukaemia follow-ing allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells", Bone marrow Transplant. 8(4), 253–258.
   PubMed Web of Science ®Google Scholar
• Datta, A.R., Barrett, A.J., Jiang, Y.Z., et al. (1994) "Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions", Bone Marrow Transplant. 14(4), 517–524.
   PubMed Web of Science ®Google Scholar
• Faber, L.M., van der Hoeven, J., Goulmy, E., et al. (1995) "Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8 + or CD4 + minor histocompatibility antigen-specific cytotoxic T lymphocytes", J. Clin. Investig. 96(2), 877–883.
   PubMed Web of Science ®Google Scholar
• Cooper, M.A., Fehniger, T.A. and Caligiuri, M.A. (2001) "The biology of human natural killer-cell subsets", Trends Immunol. 22(11), 633–640.
   PubMed Web of Science ®Google Scholar
• Ruggeri, L., Capanni, M., Martelli, M.F. and Velardi, A. (2001) "Cellular therapy: exploiting NK cell alloreactivity in transplantation", Curr. Opin. Hematol. 8(6), 355–359.
   PubMed Web of Science ®Google Scholar
• Ruggeri, L., Capanni, M., Urbani, E., et al. (2002) "Effective-ness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants", Science 295(5562), 2097–2100.
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul, P., Carter, G.I., Byrne, J.L., Hale, G. and Russell, N.H. (2002) "Compath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution", Blood 99(7), 2586–2591.
   PubMed Web of Science ®Google Scholar
• Malarkannan, S., Horng, T., Eden, P., et al. (2000) "Differences that matter: major cytotoxic T cell-stimulating minor histocompatibility antigens", Immunity 13(3), 333–344.
   PubMed Web of Science ®Google Scholar
• de Bueger, M., Bakker, A., Van Rood, J.J., Van der Woude, E and Goulmy, E. (1992) "Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens", J. Immunol. 149(5), 1788–1794.
   PubMed Web of Science ®Google Scholar
• Warren, E.H., Gavin, M., Greenberg, PD. and Riddell, S.R. (1998) "Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation", Curr. Opin. Hematol. 5(6), 429–433.
   PubMedGoogle Scholar
• Warren, E.H., Greenberg, P.D. and Riddell, S.R. (1998) "Cytotoxic T-lymphocyte-defined human minor histocom-patibility antigens with a restricted tissue distribution", Blood 91(6), 2197–2207.
   PubMed Web of Science ®Google Scholar
• Warren, E.H., Gavin, MA., Simpson, E., et al. (2000) "The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen", J. Immunol. 164(5), 2807–2814.
   PubMed Web of Science ®Google Scholar
• Wang, W., Meadows, L.R., den Harm, J.M., et al. (1995) "Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein", Science 269(5230), 1588–1590.
   PubMed Web of Science ®Google Scholar
• Goulmy, E. (1997) "Human minor histocompatibility anti-gens: new concepts for marrow transplantation and adoptive immunotherapy", Immunol. Rev. 157, 125–140.
   PubMed Web of Science ®Google Scholar
• den Haan, J.M., Meadows, L.M., Wang, W., et al. (1998) "The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism", Science 279(5353), 1054–1057.
   PubMed Web of Science ®Google Scholar
• Tseng, L.H., Lin, MT., Hansen, J.A., et al. (1999) "Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation", Blood 94(8), 2911–2914.
   PubMed Web of Science ®Google Scholar
• Dolstra, H., Fredrix, H., Maas, E, et al. (1999) "A human minor histocompatibility antigen specific for B cell acute lympho-blastic leukemia", J. Exp. Med. 189(2), 301–308.
   PubMed Web of Science ®Google Scholar
• Rickinson, A.B., Callan, M.F. and Annels, N.E. (2000) "T-cell memory: lessons from Epstein-Barr virus infection in man", Philos. Trans. R. Soc. Lond. B Biol. Sci. 355(1395), 391–400.
   PubMed Web of Science ®Google Scholar
• Rooney, CM., Smith, C.A., Ng, C.Y., et al. (1995) "Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation", Lancet 345(8941), 9–13.
   PubMed Web of Science ®Google Scholar
• Porter, D.L., Orloff, G.J. and Antin, J.H. (1994) "Donor mononuclear cell infusions as therapy for B-cell lymphopro-liferative disorder following allogeneic bone marrow trans-plant", Transplant. Sci. 4(1), 12–14.
   PubMedGoogle Scholar
• Murray, PG., Billingham, L.J., Hassan, H.T., et al. (1999) "Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease", Blood 94(2), 442–447.
   PubMed Web of Science ®Google Scholar
• Roskrow, MA., Suzuki, N., Gan, Y., et al. (1998) "Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treat-ment of patients with EBV-positive relapsed Hodgkin's disease", Blood 91(8), 2925–2934.
   PubMed Web of Science ®Google Scholar
• Rooney, CM., Roskrow, MA., Suzuki, N., Ng, C.Y., Brenner, M.K. and Heslop, H. (1998) "Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells", Ann. Oncol. 9\(Suppl. 5), S129—S132.
   PubMedGoogle Scholar
• Bocchia, M., Korontsvit, T., Xu, Q., et al. (1996) "Specific human cellular immunity to bcr-abl oncogene-derived peptides", Blood 87(9), 3587–3592.
   PubMed Web of Science ®Google Scholar
• Yotnda, P., Firat, H., Garcia-Pons, F., et al. (1998) "Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia", J. Clin. Investig. 101(10), 2290–2296.
   PubMed Web of Science ®Google Scholar
• Yotnda, P., Garcia, F., Peuchmaur, M., et al. (1998) "Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia", J. Clin. Investig. 102(2), 455–462.
   PubMed Web of Science ®Google Scholar
• Yasukawa, M., Ohminami, H., Kojima, K., et al., (2001) "HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+ ) T lymphocytes", Blood 98(5), 1498–1505.
   PubMed Web of Science ®Google Scholar
• Clark, RE., Dodi, IA., Hill, S.C., et al. (2001) "Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein", Blood 98(10), 2887–2893.
   PubMed Web of Science ®Google Scholar
• Zorn, E., Orsini, E., Wu, C.J., et al. (2001) "A CD4 + T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumour cells", Transplantation 71(8), 1131–1137.
   PubMed Web of Science ®Google Scholar
• Gao, L., Bellantuono, I., Elsasser, A., et al. (2000) "Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1", Blood 95(7), 2198–2203.
   PubMed Web of Science ®Google Scholar
• Molldrem, J., Dermime, S., Parker, K., et al. (1996) "Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferen-tially lyse human myeloid leukemia cells", Blood 88(7), 2450–2457.
   PubMed Web of Science ®Google Scholar
• Molldrem, J.J., Clave, E., Jiang, Y.Z., et al. (1997) "Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units", Blood 90(7), 2529–2534.
   PubMed Web of Science ®Google Scholar
• Treon, S.P., Maimonis, P., Bua, D., et al. (2000) "Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma", Blood 96(9), 3147–3153.
   PubMed Web of Science ®Google Scholar
• Treon, S.P., Raje, N. and Anderson, K.C. (2000) "Immunothera-peutic strategies for the treatment of plasma cell malig-nancies", Semin. Oncol. 27(5), 598–613.
   PubMed Web of Science ®Google Scholar
• Arai, J., Yasukawa, M., Ohminami, H., Kakimoto, M., Hasegawa, A. and Fujita, S. (2001) "Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lym-phocytes", Blood 97(9), 2903–2907.
   PubMed Web of Science ®Google Scholar
• Vonderheide, R.H., Hahn, W.C., Schultze, J.L. and Nadler, L.M. (1999) "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes", Immunity 10(6), 673–679.
   PubMed Web of Science ®Google Scholar
• Gaiger, A., Reese, V, Disis, M.L. and Cheever, M.A. (2000) "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia", Blood 96(4), 1480–1489.
   PubMed Web of Science ®Google Scholar
• Oka, Y., Elisseeva, O.A., Tsuboi, A., et al. (2000) "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product", Immuno-genetics 51(2), 99–107.
   PubMed Web of Science ®Google Scholar
• Ohminami, H., Yasukawa, M. and Fujita, S. (2000) "HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide", Blood 95(1), 286–293.
   PubMed Web of Science ®Google Scholar
• Molldrem, J.J., Lee, P.P., Wang, C., Champlin, R.E. and Davis, M.M. (1999) "A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T-lymphocytes from healthy donors that selectively lyse chronic myelo-genous leukemia", Cancer Res. 59(11), 2675–2681.
   PubMed Web of Science ®Google Scholar
• Molldrem, J.J., Lee, P.P., Wang, C., et al. (2000) "Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia", Nat. Med. 6(9), 1018–1023.
   PubMed Web of Science ®Google Scholar
• Ozaki, S., Kosaka, M., Wakahara, Y, et al. (1999) "Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells", Blood 93(11), 3922–3930.
   PubMed Web of Science ®Google Scholar
• Groux, H., O'Garra, A., Bigler, M., et al. (1997) "A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis", Nature 389(6652), 737–742.
   PubMed Web of Science ®Google Scholar
• Johnson, B.D., Becker, E.E., LaBelle, J.L. and Truitt, R.L. (1999) "Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy", J. Immunol. 163(12), 6479–6487.
   PubMed Web of Science ®Google Scholar
• Levings, M.K., Sangregorio, R. and Roncarolo, M.G. (2001) "Human CD25(+ )CD4(+ ) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function", J. Exp. Med. 193(11), 1295–1302.
   PubMed Web of Science ®Google Scholar
• Roncarolo, M.G., Bacchetta, R., Bordignon, C., Narula, S. and Levings, M.K. (2001) "Type 1 T regulatory cells", Immunol. Rev. 182, 68–79.
   PubMed Web of Science ®Google Scholar
• Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E. (1999) "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody", Cancer Res. 59(13), 3128–3133.
   PubMed Web of Science ®Google Scholar
• Shimizu, J., Yamazaki, S. and Sakaguchi, S. (1999) "Induction of tumor immunity by removing CD25 + CD4 + T cells: a common basis between tumor immunity and autoimmu-nity", J. Immunol. 163(10), 5211–5218.
   PubMed Web of Science ®Google Scholar
• Taylor, P.A., Noelle, R.J. and Blazar, B.R. (2001) "CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade", J. Exp. Med. 193(11), 1311–1318.
   PubMed Web of Science ®Google Scholar
• Taylor, P.A., Lees, C.J. and Blazar, B.R. (2002) "The infusion of ex vivo activated and expanded CD4(+)CD25(+ ) immune regulatory cells inhibits graft-versus-host disease lethality", Blood 99(10), 3493–3499.
   PubMed Web of Science ®Google Scholar
• Anasetti, C., Martin, P.J., Storb, R., et al. (1991) "Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3", Bone Marrow Transplant. 7(5), 375–381.
   PubMed Web of Science ®Google Scholar
• Harris, D.T., Sakiestewa, D., Lyons, C., Kreitman, R.J. and Pastan, I. (1999) "Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor", Bone Marrow Transplant. 23(2), 137–144.
   PubMed Web of Science ®Google Scholar
• Blaise, D., Olive, D., Him, M., et al. (1991) "Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients", Bone Marrow Transplant. 8(2), 105–111.
   PubMed Web of Science ®Google Scholar
• Champlin, R., Jansen, J., Ho, W., et al. (1991) "Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia", Transplant. Proc. 23(1 Pt 2), 1695–1696.
   PubMed Web of Science ®Google Scholar
• Giralt, S., Hester, J., Huh, Y, et al. (1995) "CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow trans-plantation", Blood 86(11), 4337–4343.
   PubMed Web of Science ®Google Scholar
• Alyea, E.P., Soiffer, R.J., Canning, C., et al. (1998) "Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow trans-plant", Blood 91(10), 3671–3680.
   PubMed Web of Science ®Google Scholar
• Jiang, Y.Z. and Barrett, J. (1997) "The allogeneic CD4 + T-cell-mediated graft-versus-leukemia effect", Leuk. Lymphoma 28(1-2), 33–42.
   PubMed Web of Science ®Google Scholar
• Alyea, E., Weller, E., Schlossman, R., et al. (2001) "T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect", Blood 98(4), 934–939.
   PubMed Web of Science ®Google Scholar
• Mavroudis, D.A., Dermime, S., Molldrem, J., et al. (1998) "Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions", Br. J. Haematol. 101(3), 565–570.
   PubMed Web of Science ®Google Scholar
• Garderet, L., Snell, V, Przepiorka, D., et al. (1999) "Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations", Transplantation 67(1), 124–130.
   PubMed Web of Science ®Google Scholar
• Fehse, B., Frerk, O., Goldmann, M., Bulduk, M. and Zander, A.R. (2000) "Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69)", Br. J. Haematol. 109(3), 644–651.
   PubMed Web of Science ®Google Scholar
• Guinan, E.C., Boussiotis, V.A., Neuberg, D., et al. (1999) "Transplantation of anergic histoincompatible bone marrow allografts", N. Engl. J. Med. 340(22), 1704–1714.
   PubMed Web of Science ®Google Scholar
• Tiberghien, P. (2001) "Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation", J. Intern. Med. 249(4), 369–377.
   PubMed Web of Science ®Google Scholar
• Verzeletti, S., Bonini, C., Marktel, S., et al. (1998) "Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors", Hum. Gene Then 9(15), 2243–2251.
   PubMed Web of Science ®Google Scholar
• Bonini, C. and Bordignon, C. (1997) "Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT", Hematol. Cell Ther. 39(5), 273–274.
   PubMedGoogle Scholar
• Schmaltz, C., Alpdogan, O., Horndasch, K.J., et al. (2001) "Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect", Blood 97(9), 2886–2895.
   PubMed Web of Science ®Google Scholar
• Thomis, D.C., Marktel, S., Bonini, C., et al. (2001) "A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease", Blood 97(5), 1249–1257.
   PubMed Web of Science ®Google Scholar
• Choudhury, A., Gajewski, J.L., Liang, J.C., et al. (1997) "Use of leukemic dendritic cells for the generation of antileukemic cellular cytotmdcity against Philadelphia chromosome-posi-tive chronic myelogenous leukemia", Blood 89(4), 1133–1142.
   PubMed Web of Science ®Google Scholar
• Mutis, T., Gillespie, G., Schrama, E., Falkenburg, J.H., Moss, P. and Goulmy, E. (1999) "Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lym-phocytes in patients with graft-versus-host disease", Nat. Med. 5(7), 839–842.
   PubMed Web of Science ®Google Scholar
• Kessels, H.W., Wolkers, M.C., van den Boom, M.D., van der Valk, M.A. and Schumacher, T.N. (2001) "Immunotherapy through TCR gene transfer", Nat. Immunol. 2(10), 957–961.
   PubMed Web of Science ®Google Scholar
• Stanislawski, T., Voss, R.H., Lotz, C., et al. (2001) "Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer", Nat. Immunol. 2(10), 962–970.
   PubMed Web of Science ®Google Scholar